Acquired Company

Syncona acquired Freeline Therapeutics Holdings plc by way of a scheme of arrangement, with the scheme becoming effective on February 20, 2024 and Freeline’s entire issued share capital now owned or controlled by Syncona Portfolio Limited.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops vector-mediated adeno-associated virus (AAV) transforming gene therapies for patients suffering from inherited systemic debilitating diseases. The company is headquartered in Stevenage, the United Kingdom. Show more

SYCAMORE HOUSE, STEVENAGE, UNITED KINGDOM, SG1 2BP, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, USA

https://www.freeline.life

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

28.24M

52 Wk Range

$0.00 - $0.00

Previous Close

$6.48

Open

$6.48

Volume

N/A

Day Range

$6.48 - $6.48

Enterprise Value

0.00

Cash

29.45M

Avg Qtr Burn

-8.673M

Insider Ownership

1.10%

Institutional Own.

45.88%

Qtr Updated

09/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FLT201 Details Genetic disorder, Gaucher disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FLT180a (AAVS3 capsid) Details Hemophilia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FLT190 Details Genetic disorder, Fabry disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.